A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity

This study was undertaken to determine the feasibility of enrolling breast cancer patients on a single-agent-targeted therapy trial before neoadjuvant chemotherapy. Specifically, we evaluated talazoparib in patients harboring a deleterious BRCA mutation (BRCA+). Patients with a germline BRCA mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Litton, J. K., Scoggins, M., Ramirez, D. L., Murthy, R. K., Whitman, G. J., Hess, K. R., Adrada, B. E., Moulder, S. L., Barcenas, C. H., Valero, V., Gomez, J. Schwartz, Mittendorf, E. A., Thompson, A., Helgason, T., Mills, G. B., Piwnica-Worms, H., Arun, B. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719044/
https://www.ncbi.nlm.nih.gov/pubmed/29238749
http://dx.doi.org/10.1038/s41523-017-0052-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719044/
https://www.ncbi.nlm.nih.gov/pubmed/29238749
http://dx.doi.org/10.1038/s41523-017-0052-4

Ejemplares similares